Advertisement

Topics

incorporated company of SERVIER Company Profile

19:31 EST 19th November 2017 | BioPortfolio

The leading Frenchindependent pharmaceutical company

Reference products
for diseases of major importance

17 500 employees worldwide,
including 2500 in Research and Development

Established in 140 countries

Servier turnover: 2.8 billion

Location

22 rue Garnier
NEUILLY-SUR-SEINE CEDEX
92578
France

Contact

Phone: 33 1 55 72 60 00
Email: mail.drh.genapp@fr.netgrs.com


News Articles [56 Associated News Articles listed on BioPortfolio]

Servier exercises option on OA drug rights outside USA

As part of its collaboration with Belgium-based biotech Galapagos, Servier has exercised its option to…

Servier, Transgene team up to improve tech for CAR T-cell treatments

Servier and Transgene have entered into a three-year research partnership that will analyze how Transgene's viral vectorizati -More- 

France’s Servier inks deal with Ivy League university

France’s Servier has established a three-year strategic research alliance with Harvard University to…

Harvard establishes strategic research alliance with Servier

(Harvard University) Agreement with Servier supports collaborative advancement of research in a range of therapeutic areas by researchers from across Harvard.

Servier, Transgene Leverage Platform Tech for More Effective CAR T-Cell Therapies

Servier and Transgene have established a research collaboration to evaluate the latter’s viral vectorization technologies for use in engineering allogeneic chimeric antigen receptor (CAR) T-cell the...

Servier continues global investment amid 'clear' industry demand for speed

Servier recently announced $7.5m for new technology, is doubling capacity at its Chinese facility, and is investing $58m to support biologics â a few projects among the company's effort to increase p...

Servier, Transgene partner to apply viral vectorization technology

Servier and Transgene, a biotechnology company that designs and develops immunotherapies based on viral vectors, announced the signature of a research agreement on the application of viral vectorizati...

PHILOGEN ANNONCE UN PARTENARIAT DE RECHERCHE AVEC SERVIER DANS LE DOMAINE DE LA CHIMIE ENCODÉE PAR ADN

Friday, August 25th 2017 at 6:00am UTC SIENNE, Italie–(BUSINESS WIRE)– Philogen S.p.A, une société de biotechnologie, a annoncé aujourd’hui, par l’intermédiaire de sa filia...

Clinical Trials [71 Associated Clinical Trials listed on BioPortfolio]

Epidemiology of Cardiovascular and Non-Cardiovascular Risk In Chicago

To continue the comprehensive research program on the epidemiology of cardiovascular and other major chronic diseases, including cancer and diabetes, in four Chicago population cohorts. T...

Immunogenicity and Safety of Kinrix + MMR With and Without Varicella Vaccine in Healthy Children 4-6 Years

The purpose of the study is to evaluate the immunogenicity and safety of Kinrix when co-administered with varicella (Varivax® [varicella virus vaccine live], Merck and Company) and MMR va...

Bioequivalence Study of Gliclazide 120 mg Modified Release Tablets

The main purpose of this study is to assess comparative bioavailability of two test formulations of Gliclazide 120 mg Modified Release tablets (120 mg gliclazide per modified release table...

Clinical Bioequivalence Study on Two Gliclazide 80mg Tablet Formulations

The purpose of the study is to compare the bioavailability of a generic product of gliclazide (Product Name: BF-Gliclazide Tablet 80mg, Manufactured by Bright Future Pharmaceuticals Factor...

Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fed, Healthy, Adult Subjects

- Objective: - A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Co...

Companies [1424 Associated Companies listed on BioPortfolio]

incorporated company of SERVIER

The leading Frenchindependent pharmaceutical company Reference productsfor diseases of major importance 17 500 employees worldwide,including 2500 in Research and Development Established...

SERVIER

Nil

PRAECIS PHARMACEUTICALS INCORPORATED

PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical company focused on the discovery and development of novel compounds to address unmet medical needs or improve existing therapies.PRAECIS has...

DW Coordinating Center

Since 1989, DW Coordinating Center and its partner, Clinical Pharmacological Research (CPR), St. Petersburg, Russia, have conducted major multinational clinical trials in the former Soviet Union for H...

SQI Diagnostics Inc.

SQI Diagnostics is a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics. The Company’s proprieta...

More Information about "incorporated company of SERVIER" on BioPortfolio

We have published hundreds of incorporated company of SERVIER news stories on BioPortfolio along with dozens of incorporated company of SERVIER Clinical Trials and PubMed Articles about incorporated company of SERVIER for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of incorporated company of SERVIER Companies in our database. You can also find out about relevant incorporated company of SERVIER Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record